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Simple diagnostic tests are needed for the detection of norovirus (NoV) outbreaks. Salivary antibody assays
provide an attractive alternative to collecting and testing serum or stool samples. Antibodies to Norwalk virus
(NV) in oral fluid samples were compared with NV antibodies in serum collected from 38 volunteers challenged
with NV inoculum. Pre- and postchallenge (day 4, 8, 14, and 21) saliva and serum samples were examined by
enzyme immunoassay (EIA) using recombinant NV antigen. Of 18 infected subjects (those who shed NV in
stool or who demonstrated immunoglobulin G [IgG] seroconversion), 15 (83%) had >4-fold increases in NV-
specific salivary IgA and 15 (83%) had >4-fold increases in NV-specific salivary IgG when prechallenge and
postchallenge saliva samples were compared. When the results of the IgA and IgG assays were combined, all
18 infected subjects showed >4-fold increases in NV-specific salivary IgG or IgA postchallenge titers compared
to their prechallenge titers. One of 19 uninfected subjects had a >4-fold increase in NV-specific salivary IgG.
The sensitivity of the combined assay results was 100%, and the specificity was 95%. NV-specific salivary IgA
titers peaked around 14 days postchallenge. NV-specific salivary IgG and serum IgG titers continued to rise
through 21 days postchallenge. The application of this EIA to an elementary school outbreak indicated that
67% of the subjects with confirmed infections had >4-fold rises in anti-NoV IgA when an antigen in the same
genetic cluster as the outbreak virus was used. This is the first documented mucosal antibody response to NoV
in children. This EIA provides a useful approach for diagnosing NoV outbreaks.
Norwalk virus (NV) is the prototype of a large group of
enteric viruses that are the leading cause of acute epidemic
gastroenteritis in adults and school-age children in the United
States (16). The characterization of the complete NV genome
(22, 24) and of the genomes of several related viruses (28)
established that these viruses should be classified in the family
Caliciviridae. Based on sequence analyses of the polymerase
and capsid genes, the genetically diverse human caliciviruses are
presently classified into two distinct genera, Norovirus (NoV)
and Sapovirus (International Committee on Taxonomy of Vi-
ruses Index of Viruses [http://www.ncbi.nlm.nih.gov/ICTVdb
/Ictv/index.htm]). The NoVs are further divided into two geno-
groups (I and II) (25, 37). Despite intensive efforts, the NoVs
and other human caliciviruses have not been successfully prop-
agated in cell culture, and no animal models have been iden-
tified.
NoV cases and outbreaks are being reported with increasing
frequency in the United States (7) and Europe (18a, 31) due to
improved PCR-based diagnostic assays. However, the collec-
tion of appropriate stool and serum specimens for diagnosis
remains challenging. Diagnosis of NoV infection is based pri-
marily on detecting virus particles in stool specimens by direct
electron microscopy, immunoelectron microscopy, amplifica-
tion of viral nucleic acid in stool samples by reverse transcrip-
tion (RT)-PCR, or measurement of a rise in virus-specific
serum antibody titer by enzyme immunoassay (EIA) (27). A
new commercial EIA for the detection of virus antigen in feces
has been evaluated, but the sensitivity of this assay for diag-
nosing an NoV infection is only 55% when RT-PCR is the
reference assay (47). All these approaches require the collec-
tion of fecal specimens within the first few days of illness or of
acute- and convalescent-phase sera. Historically, limitations to
these assays have included a low concentration of virus parti-
cles (44, 49), poor detection limits (104 to 105 particles/ml),
and a limited supply of natural viral antigen for serological
testing and developing reagents (21). Since the development of
recombinant NV-like (rNV) particles (23, 24), much progress
has been made in the development of sensitive EIAs to detect
NV-specific immunoglobulin A (IgA), IgG, and IgM in serum
(2, 17, 18, 36) and fecal IgA in stool (39).
While many EIAs have been described for the measurement
of virus-specific antibodies in serum, the detection of antibod-
ies in body fluids other than serum is a method that has been
relatively unexplored but which has practical benefits. Parry et
al. (41) first reviewed the use of saliva as a noninvasive alter-
native to serum for detecting virus-specific antibodies. Subse-
quently, there have been reports of EIAs that detect salivary
antibodies specific to human immunodeficiency virus (15, 33);
hepatitis A, B, and C viruses (5, 38, 42, 52); measles, mumps,
and rubella viruses (13, 43, 53); dengue virus (8); poliovirus
(19); and rotavirus (54). The collection of blood requires
trained personnel, is time-consuming, and carries a risk of
needlestick injuries (11). In contrast, saliva collection is easy
and rapid, requires little training, eliminates the risk of needle-
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stick injuries, is appropriate for both children and adults, and
is suitable for nonclinical settings. Measuring NV-specific an-
tibodies in saliva is an attractive, less-invasive alternative to
testing serum and can provide valuable information about both
the mucosal immune response and the humoral immune re-
sponse.
The objectives of this study were (i) to develop an EIA to
quantitatively detect NV-specific IgG and IgA in saliva and (ii)
to verify that the EIA can accurately diagnose NV infection in
38 volunteers challenged with NV.
MATERIALS AND METHODS
Studies of NV infectivity in human volunteers. Serum and saliva samples were
collected preinoculation and at days 4, 8, 14, and 21 postdosing from 38 adults
challenged with the 8FIIa NV inoculum (C. L. Moe, D. Rhodes, S. Pusek, F.
Tseng, W. Heizer, C. Kapoor, B. Gilliam, M. Harb, P. Stewart, S. Miller, M.
Sobsey, J. Herrmann, N. Blacklow, and R. Calderon, Abstr. 98th Gen. Meet. Am.
Soc. Microbiol., poster C-384, 1998). Saliva specimens were collected by asking
the volunteers to spit directly into a sterile 50-ml polypropylene test tube. Saliva
samples were stored at 20°C until testing.
EIA to detect NV-specific IgG in serum. The titers of anti-NV IgG in serum
specimens were determined by an EIA with rNV capsid antigen, as described by
Monroe et al. (36), with alkaline phosphatase-conjugated goat anti-human IgG
(Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.). Net absorbance was
calculated for each sample as the mean value in the duplicate antigen-coated
wells minus the mean value in the duplicate antigen-negative wells. NV sero-
conversion was defined as a 4-fold increase in NV-specific serum IgG units
based on an assigned concentration of total NoV IgG units in the reference
serum (36).
EIA to detect NV-specific IgG and IgA in saliva. Polyvinyl microtiter plates
(Dynatech Laboratories, Inc., Chantilly, Va.) were coated with either 75 l of
rNV antigen (4 g/ml in 0.025 M Tris-buffered saline [TBS; pH 7.4]) (antigen-
positive wells) or 0.025 M TBS alone (antigen-negative wells) and incubated at
room temperature for 4 h. Wells were washed twice with TBS with 0.05% Tween
20 (TBS-T) and blocked with 185 l of 5% BLOTTO (Carnation nonfat milk) in
TBS overnight at 4°C. After the wells were washed six times with TBS-T, dupli-
cate dilutions of test saliva (1:16; 75 l/well, diluted in 1% BLOTTO–TBS) were
added to two antigen-coated wells and two antigen-negative wells, and the plates
were incubated for 2 h at 37°C. After six washes with TBS-T, bound antibody was
detected by the addition of alkaline phosphatase-conjugated goat anti-human
IgG or IgA (Kirkegaard & Perry Laboratories, Inc.) (1:1,000 dilution in 1%
BLOTTO–TBS, 75 l/well) and incubated for 2 h at 37°C. After six washes with
TBS-T, 100 l of p-nitrophenylphosphate substrate (Sigma, St. Louis, Mo.) in
diethanolamine buffer (pH 9.8) was added to each well. The plates were incu-
bated in the dark at room temperature for 90 min before the optical density was
determined as the ratio of the absorbance values at 405 and 630 nm (MR 5000
microplate reader; Dynatech Laboratories, Inc.).
Known concentrations (3.1, 6.2, 12.5, 25, 50, and 100 ng/ml) of human IgG and
IgA (Sigma) were included on each plate to allow for construction of a standard
curve. The concentration of anti-NV salivary antibody was determined by com-
parison of the optical densities at 405 nm of the samples to that of the known
antibody standard curve. Results are reported as nanograms of NV-specific IgG
or IgA per milliliter. Using the convention for seroconversion, we defined NV-
specific salivary conversion as a 4-fold increase in NV-specific salivary IgG or
IgA concentration in postchallenge saliva compared to that in prechallenge
saliva.
Data analysis. The four-parameter log-logistic model was used to approximate
the sigmoidal dose-response relationship for the known antibody standard curve
(36, 45). The coefficient of variation (10) was used to evaluate between-run and
within-run assay precision. The coefficient of variation for between-run precision
was based on eight replicate tests using 16.7, 50, and 150 ng of IgG/ml for the
human IgG3() standard and 33.3, 100, and 300 ng of IgA/ml for the human IgA
standard. The coefficient of variation for within-run precision was based on 15
replicate tests of three concentrations of the IgG (50, 16.7, and 5.6 ng/ml) and
IgA (100, 33.3, and 11.1 ng/ml) standards.
NV-specific salivary antibody responses were compared to the anti-NV serum
antibody response as the reference assay to determine infection status. Infection
was defined as detection of NV RNA by RT-PCR in more than one stool sample
in the first 5 days postchallenge or a 4-fold rise in NV-specific serum IgG in day
21 postchallenge serum compared to that in prechallenge serum (Moe et al.,
Abstr. 98th Gen. Meet. Am. Soc. Microbiol.). The sensitivity of the salivary EIA
was calculated as the percentage of salivary conversions among infected subjects.
The specificity was expressed as the percentage of negative salivary conversion
test results among infected subjects. Both serum IgG units and salivary antibody
concentrations were log transformed prior to analysis.
RESULTS
Assay optimization. Initial experiments optimized the con-
centration of the rNV used as coating antigen, the dilution of
the test saliva, and the dilution of the conjugated secondary
antibody to provide the best discrimination between known
infected and uninfected individuals. Saliva samples from in-
fected volunteers were tested at dilutions ranging from 1:4 to
1:256. Subsequently, a single test dilution (1:16) was chosen
because it provided the best assay sensitivity and specificity and
consistently demonstrated a 4-fold increase in NV-specific
salivary IgG or IgA when preexposure saliva samples and saliva
samples collected 21 days postchallenge from NV-infected vol-
unteers were compared.
Assay precision. Calculation of the coefficients of variation
provided a measure of the precision of the assay between runs
and within runs at three concentrations of the immunoglobulin
standards. The coefficient of variation for between-run preci-
sion ranged from 8.0 to 16.8 for the salivary IgA EIA and 0.6
to 12.8 for the salivary IgG EIA (data not shown). The within-
run coefficients of variation for IgA and IgG salivary EIAs
ranged from 13.6 to 18.4 and 1.9 to 8.7, respectively (data not
shown). The precision of our salivary EIAs was comparable to
that reported for salivary antibody detection assays for other
viruses. Madsen et al. (32) reported a 15.6% within-run coef-
ficient of variation for an enzyme-linked immunosorbent assay
used to screen and quantitate IgG antibodies to rubella virus,
and Friedman (13) reported a 19.3% within-run coefficient of
variation for the detection of mumps virus-specific IgA anti-
bodies in saliva.
Salivary antibody response to NV infection. Eighteen (47%)
of the 38 volunteers had 4-fold rises in NV-specific serum
IgG by 21 days postchallenge and were classified as infected.
All infected volunteers also shed NV (detected by RT-PCR) in
more than one stool sample in the first 5 days postchallenge.
No individuals who shed NV failed to demonstrate serocon-
version. Seroconversion occurred in 13 of 18 (72%) infected
volunteers between 5 and 8 days postchallenge (Table 1).
Three of the remaining five volunteers showed seroconversion
by day 14, and the remaining two demonstrated seroconversion
by day 21. The NV-specific salivary IgA response occurred
TABLE 1. Detection of NV-specific antibodies in serum and saliva
specimens collected from 18 infected volunteers
Antibody
No. (cumulative %) of subjects with 4-
fold increase in antibodies on daya:
4 8 14 21
NV-specific serum IgG 0 (0) 13 (72) 3 (89) 2 (100)
NV-specific salivary antibody
IgA 6 (33) 3 (50) 4 (72) 2 (83)
IgG 3 (17) 7 (56) 3 (72) 2 (83)
a Day postchallenge at which 4-fold increase in antibody titer was first de-
tected, in comparison to prechallenge specimen titer.
VOL. 11, 2004 SALIVARY IMMUNOASSAY FOR NORWALK VIRUS 1029
earlier than the salivary and serum IgG responses. Of the 18
infected volunteers, a total of 15 (83%) had 4-fold increases
in NV-specific salivary IgA, and 6 of these volunteers showed
4-fold increases in NV-specific salivary IgA by 4 days post-
challenge (Table 1). The anti-NV salivary IgG response was
generally of a greater magnitude than the salivary IgA re-
sponse and usually occurred several days later, with 56% of the
infected volunteers showing 4-fold increases in anti-NV sal-
ivary IgG titer by day 8 postchallenge (Table 1). For the 18
infected volunteers, the average ratio of the highest postchal-
lenge NV-specific antibody titer (from day 8, 14, or 21) to the
prechallenge anti-NV titer was 78.1 (range, 4.2 to 250) for
serum IgG, 47.2 (range, 1.4 to 205) for salivary IgG, and 25.1
(range, 1.0 to 74) for salivary IgA (Table 2). Among the 18
infected volunteers, NV-specific serum IgG and salivary IgG
titers started to rise by day 4 postchallenge and continued to
rise through day 21 postchallenge (Table 3). The geometric
mean concentration of NV-specific salivary IgG increased
from 26 ng/ml (range, 5 to 383) at baseline to 47 ng/ml on day
4 postchallenge, 102 ng/ml on day 8, 237 ng/ml on day 14, and
398 ng/ml on day 21. The geometric mean NV-specific salivary
IgA titers were somewhat higher than the salivary IgG titers;
however, the titer peaked at day 14 postchallenge (Table 3).
For the 18 infected volunteers, the geometric mean NV-spe-
cific salivary IgA concentration was 46 ng/ml (range, 11 to 199)
at baseline, increased to 80, 252, and 338 ng/ml by days 4, 8,
and 14, respectively, and then decreased to 269 ng/ml by day 21
postchallenge.
Comparison of serum and salivary EIAs. There was good
agreement between NV-specific salivary IgA and salivary IgG
responses in individual volunteers. With 4-fold increases in
salivary NV-specific IgG or IgA considered indicative of NV
infection, 12 volunteers demonstrated salivary conversions in
both the IgG and IgA assays, and 19 volunteers did not dem-
onstrate conversions in either assay, yielding a total of 31
(82%) volunteers with concordant results (Fig. 1). Three (8%)
of the salivary specimen pairs showed salivary IgA conversions
but not salivary IgG conversions. Four (11%) salivary speci-
men pairs showed salivary IgG conversions but not salivary IgA
conversions.
There was overall agreement between serum and salivary
IgG responses for 34 of 38 (89%) volunteers (Fig. 2, top panel)
and between serum IgG and salivary IgA responses for 35 of 38
(92%) volunteers (Fig. 2, bottom panel). We detected 4-fold
rises in NV-specific salivary IgG and IgA titers in 15 (83%) of
the 18 volunteers who had 4-fold rises in NV-specific serum
IgG titers. Compared to the reference assays for NV-specific
serum IgG, the EIA for NV-specific salivary IgA and IgG had
83% sensitivity. None of the 20 uninfected subjects demon-
strated seroconversion. Nineteen had negative salivary IgG tests,
and all 20 had negative salivary IgA tests, indicating specifici-
ties of 95 and 100% for the NV-specific salivary IgG and IgA
EIAs, respectively. One uninfected volunteer had a 4.4-fold
increase in anti-NV salivary IgG but did not show seroconver-
sion or have a 4-fold increase in anti-NV salivary IgA.
Application of salivary EIA to NoV outbreak investigations.
In order to evaluate the use of the salivary EIA for NoV
outbreak investigations, we compared the anti-NV salivary ti-
ters in samples from day 4 postchallenge to the titers in the
samples from day 14 postchallenge because those days seemed
like the most feasible sample collection times in an outbreak
FIG. 1. Comparison of NV-specific salivary IgA and IgG conver-
sions. Each symbol represents the increase (n-fold) in antibody re-
sponse in paired saliva specimens (prechallenge and day 21 postchal-
lenge) from a single individual that were assayed for both NV-specific
IgA and IgG. The broken vertical and horizontal lines indicate the
fourfold minimum increases that define an infection. Points to the
right of the broken vertical line represent salivary conversions defined
by a 4-fold increase in salivary IgG. Points above the horizontal
broken line represent salivary conversions defined by a 4-fold in-
crease in IgA. N, number of saliva specimens represented in each
quadrant of the plot.








Range Mean Range Mean
Serum IgG 4.2–250 78.1 0.04–3.4 1.1
Salivary
IgG 1.4–205 47.2 0.2–4.4 1.2
IgA 1.0–74 25.1 0.5–2.6 1.2
a Antibody reactivity is defined as the ratio of NV-specific serum IgG units or
NV-specific salivary IgG or IgA concentration at highest postchallenge titer
versus prechallenge titer. Specimens were collected from 38 NV-challenged
volunteers.






Prechallenge 8,129 26 46
Postchallenge, day:
4 8,499 47 80
8 50,216 102 252
14 89,989 237 338
21 130,903 398 269
a Expressed in NV-specific IgG units of a standard control serum.
b Expressed in nanograms per milliliter by using a standard curve of known
antibody concentration.
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investigation. Fourteen of the 18 infected subjects had 4-fold
rises in NV-specific antibody titers (IgA or IgG), giving an
assay sensitivity of 78% (data not shown). Of the four subjects
who did not have a salivary conversion during this time inter-
val, two had early rises in anti-NV salivary IgA or IgG titer (by
day 4 postchallenge) and the other two had late rises in an-
ti-NV salivary IgA or IgG titer (by day 21). Only 1 of the 20
uninfected subjects had a 4-fold rise in anti-NV salivary an-
tibody titer, giving an assay specificity of 95%.
In a trial application of this assay to an NoV outbreak with
approximately 100 cases in an elementary school, we were able
to collect stool specimens and paired acute- and convalescent-
phase saliva samples from nine infected subjects, one exposed
control subject, and four unexposed control subjects (Table 4).
The infected subjects were seven schoolchildren who were
willing to provide specimens, one adult, and the school nurse.
The exposed control subject was a schoolchild who was not ill,
and the unexposed control subjects were Health Department
employees who investigated the outbreak. Acute-phase saliva
was collected 0 to 4 days after the onset of symptoms (mean,
2.8 days). Convalescent-phase saliva was collected 18 to 37
days after onset (mean, 22.9 days). NoV RNA could be de-
tected in stool specimens from eight of nine infected subjects
by RT-PCR, and sequencing and phylogenetic analyses of the
81-bp PCR product of the polymerase gene indicated that for
the seven children, the virus was a genogroup I NoV in the
Desert Shield virus (DSV) cluster (GI/3). The school nurse was
infected with a genogroup II NoV and became ill 5 days after
the children. None of the Health Department employees were
infected. Ten saliva specimens were tested against both the
rNV antigen and a recombinant antigen from a DSV-like virus
(VA98115; generously provided by Xi Jiang). Four additional
specimens (including one from an RT-PCR-confirmed geno-
group I NoV case) were of insufficient volume for both assays
and were tested only with the NV antigen. For the RT-PCR-
confirmed genogroup I NoV-infected subjects, two had 4-
fold rises in anti-NoV salivary IgA titer with the NV protein
and four had 4-fold rises in anti-NoV salivary IgA titer with
the DSV-like protein. Two subjects with confirmed infections
had 4-fold rises in anti-DSV-like salivary IgG titer. The me-
dian rises in anti-DSV-like salivary antibody titer for six NoV
genogroup I-infected subjects were 17.1 for IgA and 2.7 for
IgG. None of the paired saliva specimens collected from the six
people with RT-PCR-negative stools showed a 4-fold rise in
anti-DSV-like or anti-NV salivary IgA or IgG. These results
suggest that the salivary IgA assay with the DSV-like antigen
was effective for detecting a genogroup I NoV outbreak.
DISCUSSION
NoVs are the leading cause of acute epidemic gastroenter-
itis. Currently, diagnosis rests on the detection of viral RNA in
FIG. 2. Comparison of NV-specific seroconversions and salivary
conversions. Each symbol represents the increase (n-fold) in antibody
response in paired (prechallenge and day 21 postchallenge) serum and
saliva specimens from a single individual that were assayed for both
NV-specific serum IgG and NV-specific salivary IgA and IgG. The
broken vertical and horizontal lines indicate the fourfold minimum
increases that define infection. Points to the right of the broken vertical
lines represent seroconversions defined by a 4-fold increase in serum
IgG. Points above the horizontal broken line represent salivary con-
versions defined by a 4-fold increase in salivary IgG (top panel) or
IgA (bottom panel). N, number of saliva specimens represented in
each quadrant of the plot.









Genogroup I (n  7) 2/7 (29) 4/6 (67) 2/6 (33)
Genogroup II (n  1) 0/1 NT NT
NoV negative (n  6) 0/6 0/4 0/4
a RT-PCR results from stool specimens.
b Expressed as number of specimens positive for indicated antibody/total num-
ber of specimens tested. Percentages are given in parentheses. Positivity was
indicated by a 4-fold rise in salivary antibody titer between acute- and conva-
lescent-phase samples. NT, not tested.
c IgA test using NV antigen.
d IgA and IgG tests using DSV-like antigen. For these data, some samples
were not tested because of insufficient sample volume.
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stool within the first few days of symptoms or evidence of a
fourfold rise in anti-NoV serum IgG in acute and convalescent-
phase sera, and it is often challenging to collect satisfactory
clinical specimens in outbreak investigations to confirm the
cause and extent of the outbreak. Our overall goal was to
develop an EIA to diagnose recent NoV infection and NoV
outbreaks based on the detection of a rise in NoV-specific
salivary IgA or IgG in a high proportion of subjects. With saliva
specimens from volunteers in an NV challenge study, our re-
sults indicate that NV-specific IgG and IgA salivary conversion
is a reliable indicator of NV infection. Our EIA for NV-specific
salivary IgA and IgG had a sensitivity of 83% and a specificity
of 95 to 100%. The magnitude of the rise in NV-specific sali-
vary antibody concentrations in infected volunteers was sub-
stantial (means, 47.2 for IgG and 25.1 for IgA), although not as
great as the mean rise in NV-specific serum IgG (78.1). In our
application of the assay to a limited number of specimens from
an elementary school outbreak, 67% of the infections could be
detected by a 4-fold rise in anti-NoV IgA by use of an antigen
that was in the same genetic cluster as the outbreak virus. This
is the first documented mucosal antibody response to NoVs in
children.
Since the 1980s, there have been a growing number of re-
ports of the development and application of salivary antibody
assays to diagnose viral infections (1, 3, 4, 6, 12, 14, 20, 29, 38,
40, 43, 46, 52). The sensitivity of our EIA for NV-specific
salivary IgA and IgG conversion (83%) is similar to that re-
ported for antirotavirus salivary IgA conversion in adult vol-
unteers challenged with human rotavirus (75% by 13 to 27 days
postchallenge) (54). Most previous salivary assays have simply
detected the presence of virus-specific salivary antibodies and
reported high sensitivity and specificity. However, because
most of the volunteers had anti-NV salivary IgA (95%) and
IgG (71%) in their baseline samples, we used our EIA to
examine the rise in NV-specific salivary antibodies following
infection. This approach requires paired specimens from the
same individual.
Our results from the NV challenge studies on the time
course of various components of the host immune response
provide guidance on timing specimen collection for accurate
diagnosis. We observed that the average NV-specific salivary
IgA levels in infected volunteers peaked at day 14 postchal-
lenge and decreased by day 21 (Table 3). This pattern was also
observed in the salivary IgA response to rotavirus in infected
adult volunteers (54). Some of our results suggested that the
salivary IgA response started quite early, because six subjects
had 4-fold rises in NV-specific salivary IgA by day 4 post-
challenge. However, when we retested the specimens from
three of these subjects for which there was sufficient sample
volume, we found that the ratio of NV-specific salivary IgA to
total salivary IgA on day 1 versus that on day 4 postchallenge
indicated that there was no salivary conversion by day 4. This
finding confirms a recent report (30) that, in infected volun-
teers, there can be an initial release of total salivary IgA in the
first 5 days postchallenge but that (i) the ratio of the NV-
specific IgA to total salivary IgA remains relatively constant or
shows only a modest rise during this time and (ii) most of the
new NV-specific salivary antibodies are made 5 to 14 days
postchallenge. In contrast, NV-specific salivary and serum IgG
levels continued to increase through day 21 postchallenge. NV
seroconversion usually occurred around day 8 postchallenge.
Because the magnitude of the NV-specific salivary antibody
increase and the timing of the peak levels differ among infected
individuals (data not shown), it is not possible to diagnose an
NV infection with a single sample. However, by comparing
anti-NV salivary antibody titers of acute-phase samples col-
lected as early as possible during infection to those of conva-
lescent-phase specimens collected around 14 days postexpo-
sure, it should be possible to reliably detect the majority of NV
infections by this approach. With the day 4 and 14 postchal-
lenge saliva samples from volunteers, the sensitivity of this
salivary antibody assay for detecting NV infection (78%) is
better than that reported for a commercially available NoV
antigen detection EIA (71.4% when six or more specimens
from an outbreak were tested), and the specificity of the sali-
vary assay (95 to 100%) is similar to that of the commercial
antigen detection EIA (100% when six or more specimens
from an outbreak were tested) (47).
The clinical sensitivity of the salivary antibody EIA and the
overall consistency of our findings suggest that this is a robust
assay despite a range in antibody levels and sample integrity.
Salivary antibody levels are influenced by the flow rate of saliva
(35). A variety of factors, including food ingestion, diet, sen-
sory stimulation, drugs, smoking, stress, exercise, and degree of
hydration, can influence the salivary flow and antibody con-
centrations (9, 48, 50, 55). Our study tested almost 200 saliva
samples collected from 38 volunteers over a 2.5-year study
period, and some of these samples had been stored at 20°C
for up to 5 years, which may have caused some degradation
(43, 51).
The evidence that salivary antibody concentrations can be
influenced by many extrinsic factors may explain some of the
individual fluctuations that we observed in NV-specific salivary
IgA and IgG antibody concentrations over time and some of
the discrepancies between anti-NV IgG seroconversion and
anti-NV salivary antibody conversions. Three volunteers who
showed seroconversion did not show corresponding fourfold
increases in NV-specific salivary IgG, and three different vol-
unteers who showed seroconversion did not have fourfold in-
creases in NV-specific salivary IgA. However, if the results of
both the salivary IgG and the salivary IgA conversions are
combined, all of the NV-infected volunteers were correctly
classified, and one volunteer who did not show seroconversion
and who did not shed virus would have been incorrectly clas-
sified as infected by the NV-specific salivary IgG EIA.
Salivary antibody assays for other viruses have been used for
a variety of research and surveillance applications, including
hepatitis A virus outbreak investigations (4), poliovirus and
rotavirus vaccine studies (6, 14), measles virus surveillance
studies (3), and studies of host immune responses to viral
infection (46). Salivary assays are also useful for populations in
developing countries, pediatric populations, and difficult-to-
serve-populations, such as intravenous drug users. From both
clinical and epidemiological perspectives, diagnostic assays
based on saliva or another oral fluid offer many advantages
over serum-based assays (40). Collecting saliva specimens is far
easier than collecting stool or serum specimens and is associ-
ated with fewer refusals by subjects to provide specimens. It is
more convenient and less expensive because it is possible to
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train subjects to collect specimens from themselves and does
not require a trained phlebotomist. In our experience, saliva
collection was well accepted by healthy volunteers in clinical
trials and children involved in NoV outbreaks.
The epidemiological significance of this study is that the
detection of NV-specific antibodies in saliva is a reliable, non-
invasive method for the diagnosis of NV infection that could be
well suited for outbreak investigations and that could lead to
greater recognition of NoV outbreaks. Although our knowl-
edge of the role of NoVs in epidemic gastroenteritis has in-
creased dramatically since the advent of RT-PCR techniques
and recombinant NoV antigens, epidemic NoV infections are
probably greatly underestimated, because infected persons of-
ten do not seek medical attention and are often reluctant to
provide stool or serum specimens. While the incidence of in-
dividual NoV infections may be underestimated by this assay,
a salivary antibody assay with a pool of representative recom-
binant NoV antigens should prove useful for detecting or con-
firming a NoV outbreak if multiple specimens are available for
testing. Assays for salivary antibodies may also be useful for
population-based prospective studies of endemic NoV infec-
tion. The collection of saliva specimens at 2-week intervals
would capture the rapid rise and fall of NoV-specific salivary
antibody titers and could be used to estimate the incidence of
NoV infection in longitudinal studies. This salivary antibody
assay together with analyses of histo-blood group antigens and
salivary binding studies could lead to major advances in our
knowledge of NoV susceptibility and infection.
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